Outsourced Manufacturing: A Swiss Specialty
Unknown to some, Switzerland meanwhile remains both influential and relevant in global pharma circles not just for the obvious core activities of research, discovery and marketing, but also for its…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Switzerland AG
Zählerweg 6
CH 6300 Zug
Switzerland
Phone: +41 41 728 7444
Fax: +41 41 728 7440
www.biogenidec.ch
International Headquarters
Biogen Idec International GmbH
Landis & Gyr-Strasse 3
CH 6300 Zug
Switzerland
Phone: +41 41 39 21700
Fax: +41 41 39 21710
www.biogenidec-international.com
Unknown to some, Switzerland meanwhile remains both influential and relevant in global pharma circles not just for the obvious core activities of research, discovery and marketing, but also for its…
With cancer now causing one in eight deaths globally and, in Europe, even outpacing serious cardiovascular conditions in terms of prevalence, Switzerland has long positioned itself firmly at the vanguard…
Indian generics powerhouse Dr. Reddy’s has prioritized biosimilars as a key component of the global organization’s ongoing transition into a specialty pharma company. As one of the first companies…
Worldwide, severe side effects from classic medicine are becoming a health risk in themselves, often misdiagnosed as symptoms of other problems, resulting in further prescriptions, further side effects and unanticipated drug interactions;…
In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants,…
Roche announced strong Group sales growth of seven percent for 2018, partly driven by the launch of MS blockbuster Ocrevus, which CEO Severin Schwan has described as the most successful…
Basel-headquartered pharma giant Novartis announced its financial results for 2018 this week, showcasing full year net sales growth of five percent driven by the strong performance of the company’s pharmaceutical…
The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined…
In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models,…
The past 5 decades have seen monumental strides in healthcare; from the discovery that aspirin prevents blood clotting to the eradication of smallpox. In this exclusive interview, Thomas Cueni, director general…
As the spotlight turns towards optimising supply and delivery chains in pharma logistics, Swiss Post has distinguished itself as one of the early movers in trialling autonomous drone logistics for…
Alexander Bauer, chairman and co-founder of 4PL Central Station, introduces his company’s unique logistics service offering, and the role of fourth party logistics in the future of the pharmaceutical industry.…
See our Cookie Privacy Policy Here
